Immunomic Therapeutics’ Collaborator, a University of Florida Researcher, Presents New Clinical Data at the 2019 Society for Neuro-Oncology (SNO) Annual Meeting (Business Wire)

Immunomic Therapeutics’ Collaborator, a University of Florida Researcher, Presents New Clinical Data at the 2019 Society for Neuro-Oncology (SNO) Annual Meeting

Immunomic Therapeutics, Inc., a privately-held clinical-stage biotechnology company pioneering the study of nucleic acid immunotherapy platforms, announced that Duane Mitchell, MD, Ph.D., a University of Florida professor of neurosurgery and co-director of the Preston A. Wells Jr. Center for Brain Tumor Therapy and his team, will present new clinical data at the 2019 Society for Neuro-Oncology (SNO) Annual Meeting being held in Phoenix, Arizona.

The data being presented at the SNO meeting are from a Phase 2 clinical trial (ATTAC-II) evaluating the efficacy of autologous CMV pp65-LAMP RNA pulsed dendritic cell vaccines mixed with GM-CSF and administered during cycles of adjuvant dose-intensified temozolomide. The results demonstrate that a CMV pp65-LAMP RNA-pulsed DC vaccination was associated with profound immunologic and clinical response in a patient with MGMT unmethylated midline glioblastoma (GBM).

Learn more about Immunomic Therapeutics’ Collaborator, a University of Florida Researcher, Presents New Clinical Data at the 2019 Society for Neuro-Oncology (SNO) Annual Meeting.
X